INDEGENE Latest Share Price (INDGN)
TODAY IN ONE LINE
INDGN slipped 0.7% on average volume, in line with Nifty's -0.4% move, supported by recent strong earnings.
With a market cap of ₹14,288.59 Cr., it trades at a P/E of 35.59. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
INDEGENE flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Quarterly OutperformanceLatest quarter Sales up 212.0% and Profit up 94.0%
- ●Healthy Operating MarginsOPM is structurally strong at 15.5%
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
- ●Positive Free Cash FlowFCF has been positive for 3 consecutive years
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Earnings DeclineEPS (TTM) has contracted by 32.3% YoY
- ●Rising Receivables vs SalesReceivables grew 18.4% outpacing sales growth of 9.6%
Latest INDEGENE News
What changed recently?
Recent events, corporate actions, and announcements.
INDEGENE valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for INDEGENE, framed against the sector median so the premium or discount is obvious at a glance.
INDEGENE trades at a P/E of 35.59× and P/B of 4.55×, against the Healthcare sector median P/E of 46.64×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
INDEGENE technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for INDEGENE — derived from the latest tape, not yesterday's close.
INDEGENE last traded at ₹592.1 with an intraday range of ₹588–₹600.35 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹592.10| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 623.67 | +31.57 | +5.33% |
| R3 | 611.32 | +19.22 | +3.25% |
| R2 | 605.83 | +13.73 | +2.32% |
| R1 | 598.97 | +6.87 | +1.16% |
| PIVOT | 593.48 | 1.38 | 0.23% |
| CURRENT | 592.10 | — | — |
| S1 | 586.62 | -5.48 | -0.93% |
| S2 | 581.13 | -10.97 | -1.85% |
| S3 | 574.27 | -17.83 | -3.01% |
| S4 | 561.92 | -30.18 | -5.10% |
INDGN is trading Below CPR, indicating Bearishness
CPR is Average
Day's range: ₹594.25–₹599.55
Trading Below opening range, showing Bearishness
INDEGENE financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for INDEGENE — consolidated or standalone — with margins, YoY growth and key ratios inline.
INDEGENE reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹14,288.59 Cr. and reported EPS of ₹16.62.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 2,839 | 3,511 ▲ 23.6% |
| Sales Growth YoY %Derived | 9.64% | 23.64% |
| Other Income | 107 | 72 ▼ 32.8% |
| Total Income | 2,947 | 3,583 ▲ 21.6% |
| Gross ProfitDerived | 2,839 | 3,511 ▲ 23.6% |
| Gross Margin %Derived | 100.00% | 100.00% |
| 2,305 | 2,892 ▲ 25.4% | |
| EBITDA (Operating Profit)Derived | 534 | 619 ▲ 15.9% |
| OPM %Derived | 18.82% | 17.63% |
| 102 | 125 ▲ 22.7% | |
| Profit Before Tax (PBT) | 539 | 525 ▼ 2.7% |
| 133 | 124 ▼ 6.6% | |
| Effective Tax %Derived | 24.59% | 23.60% |
| Total Profit for Period | 407 | 401 ▼ 1.4% |
| Net Profit (Owner's PAT)Derived | 407 | 401 ▼ 1.4% |
| Net Profit Margin %Derived | 14.32% | 11.43% |
| PAT Growth YoY %Derived | 20.79% | -1.38% |
| Earnings Per Share (EPS ₹) | 16.95 | 16.65 ▼ 1.8% |
| Diluted Shares Outstanding (Cr) | 24 | 24 ▲ 0.4% |
| Other Comprehensive Income (Net of Tax) | 26 | 139 ▲ 444.5% |
| Total Expenses (incl. D&A & Interest) | 2,407 | 3,058 ▲ 27.0% |
| Material Cost % of RevenueDerived | — | — |
| Employee Cost % of RevenueDerived | 63.93% | 62.60% |
| Other Cost % of RevenueDerived | 17.25% | 19.76% |
| Interest Coverage (x)Derived | 20.64x | 25.52x |
| Period | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|
| Revenue from Operations | 2,590 | 2,839 ▲ 9.6% | 3,511 ▲ 23.6% | |
| Sales Growth YoY %Derived | — | 9.64% | 23.64% | |
| Other Income | 76 | 107 ▲ 40.5% | 72 ▼ 32.8% | |
| Total Income | 2,666 | 2,947 ▲ 10.5% | 3,583 ▲ 21.6% | |
| Gross ProfitDerived | 2,590 | 2,839 ▲ 9.6% | 3,511 ▲ 23.6% | |
| Gross Margin %Derived | 100.00% | 100.00% | 100.00% | |
2,084 | 2,305 ▲ 10.6% | 2,892 ▲ 25.4% | ||
| EBITDA (Operating Profit)Derived | 505 | 534 ▲ 5.7% | 619 ▲ 15.9% | |
| OPM %Derived | 19.52% | 18.82% | 17.63% | |
128 | 102 ▼ 20.1% | 125 ▲ 22.7% | ||
| Profit Before Tax (PBT) | 459 | 539 ▲ 17.6% | 525 ▼ 2.7% | |
122 | 133 ▲ 8.8% | 124 ▼ 6.6% | ||
| Effective Tax %Derived | 26.58% | 24.59% | 23.60% | |
| Total Profit for Period | 337 | 407 ▲ 20.8% | 401 ▼ 1.4% | |
| Net Profit (Owner's PAT)Derived | 337 | 407 ▲ 20.8% | 401 ▼ 1.4% | |
| Net Profit Margin %Derived | 13.00% | 14.32% | 11.43% | |
| PAT Growth YoY %Derived | — | 20.79% | -1.38% | |
| Earnings Per Share (EPS ₹) | 14.07 | 16.95 ▲ 20.5% | 16.65 ▼ 1.8% | |
| Diluted Shares Outstanding (Cr) | 24 | 24 ▲ 0.3% | 24 ▲ 0.4% | |
| Other Comprehensive Income (Net of Tax) | 8 | 26 ▲ 224.1% | 139 ▲ 444.5% | |
| Total Expenses (incl. D&A & Interest) | 2,207 | 2,407 ▲ 9.1% | 3,058 ▲ 27.0% | |
| Material Cost % of RevenueDerived | — | — | — | |
| Employee Cost % of RevenueDerived | 63.78% | 63.93% | 62.60% | |
| Other Cost % of RevenueDerived | 16.71% | 17.25% | 19.76% | |
| Interest Coverage (x)Derived | 8.69x | 20.64x | 25.52x |
INDEGENE segment analysis : revenue and profit mix.
Disclosed business segments at INDEGENE with their share of revenue and profit, switchable between consolidated and standalone reporting.
INDEGENE discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for INDEGENE.
Our AI distills the core fundamental drivers supporting INDEGENE, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
INDEGENE's investment case rests on 0 positive markers and 1 flagged concerns drawn from the latest reported filings.
What you're getting.
No strengths or opportunities on record.
Key Risks.
SWOT generation temporarily unavailable due to model error. The security token included in the request is invalid.
Flip Conditions.
Valuation risk. a P/E above 46 (~1.0× the sector multiple of 46.6) would leave less room for earnings disappointment.
Fundamental risk. a shrinking deal pipeline (TCV) or margins below historical averages would weaken the thesis.
Watch wage inflation and attrition rates — primary threats to operating leverage in IT.
Return-quality risk. ROE below 8% would indicate weaker capital compounding.
INDEGENE peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — INDEGENE is highlighted for quick read-across.
Quick Compare
INDEGENE chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for INDEGENE — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
INDEGENE delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for INDEGENE over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in INDEGENE stood at 46.6% of traded volume, against a 20-day average of 55.9%.
INDEGENE announcements: results, concalls, ratings, M&A.
Filings INDEGENE sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
INDEGENE files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 215 documents below.
Amalgamation/Merger
Indegene Limited has informed the Exchange about Amalgamation/Merger of Indirect Wholly Owned Subsidiaries of the Company in Germany
Analysts/Institutional Investor Meet/Con. Call Updates
Indegene Limited has informed the Exchange about Schedule of meet
Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company
Indegene Limited has informed the Exchange about Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company
Analysts/Institutional Investor Meet/Con. Call Updates
Indegene Limited has informed the Exchange about Schedule of meet
Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company
Indegene Limited has informed the Exchange about Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company
Investor decks & rating reports.
Investor Presentation
Analysts/Institutional Investor Meet/Con. Call Updates
Analysts/Institutional Investor Meet/Con. Call Updates
Analysts/Institutional Investor Meet/Con. Call Updates
INDEGENE dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue INDEGENE has declared, sequenced by announce and record date.
INDEGENE corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
INDEGENE insider trading: promoter and management activity.
Promoter, director and designated-employee transactions in INDEGENE as reported to SEBI — buying and selling signals from the people who know the business best.
INDEGENE insider activity below tracks 9 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).
| Insider | Category | Txn Date | Action | Quantity | Value (₹) | Price |
|---|---|---|---|---|---|---|
| Anita Nair | Insider | 19 Mar 2026 | buy | +22.2 K | ₹99.98 L | ₹449.76 |
| Anita Nair | Insider | 19 Mar 2026 | buy | +22.2 K | ₹99.98 L | ₹449.76 |
| Anita Nair | Insider | 19 Mar 2026 | buy | +22.2 K | ₹99.98 L | ₹449.76 |
| Anita Nair | Insider | 19 Mar 2026 | buy | +22.2 K | ₹99.98 L | ₹449.76 |
| Anita Nair | Insider | 19 Mar 2026 | buy | +22.2 K | ₹99.98 L | ₹449.76 |
| Manish Gupta | Insider | 24 Dec 2024 | buy | +17.0 K | ₹1.02 Cr. | ₹599.19 |
| Rajesh Bhaskaran Nair | Insider | 23 Dec 2024 | buy | +25.0 K | ₹1.5 Cr. | ₹598.26 |
| Sanjay Suresh Parikh | Insider | 20 Dec 2024 | buy | +16.5 K | ₹1 Cr. | ₹606.52 |
| Rajesh Bhaskaran Nair | Insider | 17 Dec 2024 | buy | +1.00 L | ₹5.96 Cr. | ₹595.81 |
About INDEGENE: business, sector, key facts.
What INDEGENE does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
INDEGENE operates in the Healthcare Research Analytics & Technology industry under the Healthcare sector, listed as NSE: INDGN, BSE: 544172.
Indegene Limited is a global digital-first life sciences commercialization company headquartered in Bengaluru, India, with a significant presence in the United States and Europe. The company's core business revolves around providing comprehensive services and technology solutions to biopharmaceutical, emerging biotech, and medical device companies across their entire product lifecycles.
Indegene's operations are structured into three primary segments: Enterprise Medical Solutions, Enterprise Commercial Solutions, and Omnichannel Activation & Others. The Enterprise Medical Solutions segment focuses on providing medical and clinical solutions, supporting the development and regulatory aspects of new products. This likely includes services such as medical affairs, regulatory strategy, and clinical trial support.
The Enterprise Commercial Solutions segment caters to the commercial aspects of bringing products to market. This likely encompasses services such as market research, sales force effectiveness, pricing and market access strategy, and overall commercial strategy development and execution. These services are crucial for maximizing product uptake and return on investment.
The Omnichannel Activation & Others segment likely incorporates a range of solutions aimed at integrating various channels for effective communication and engagement with healthcare professionals and patients. This might include digital marketing, content creation, and multi-channel campaign management to promote products and build brand awareness. The "Others" component likely encompasses additional services that complement the core offerings, potentially including consulting or specialized technology services.
A key aspect of Indegene's business model is its reliance on NEXT technology platforms. These platforms likely represent a suite of proprietary technologies and tools designed to enhance efficiency and effectiveness across its various service offerings. These platforms could include data analytics dashboards, CRM systems tailored for the life sciences industry, or other specialized software.
In summary, Indegene acts as a comprehensive partner for life sciences companies, providing a blend of consulting, technology, and services to navigate the complexities of research, development, and commercialization. Their integrated approach across medical, commercial, and omnichannel activation ensures a holistic support system for clients throughout the entire product lifecycle.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- SUVEN LIFE SCIENCES (SUVEN) Share PricePeer
- SYNGENE INTERNATIONAL (SYNGENE) Share PricePeer
- TAKE (TAKE) Share PricePeer
- VIMTA LABS (VIMTALABS) Share PricePeer
- Stocks near 52-week high (breakout watch)Screener
- Breakout Trader strategy playbookStrategy
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about INDEGENE (INDGN).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of INDEGENE (INDGN)?
The current share price of INDEGENE (INDGN) is ₹592.10. Today, the stock has declined by ₹3.85 (0.65%), trading in a range of ₹588.00 to ₹600.35. The stock opened at ₹596.00 with a trading volume of 1,92,223 shares.
02Is INDEGENE stock a good investment for long-term?
INDEGENE can be considered for long-term investment based on several factors. The company has a market capitalization of ₹14,288.59 Cr., P/E ratio of 35.59, ROE of 12.78%, and ROCE of 14.54%. The dividend yield stands at 0.37%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of INDEGENE stock?
The 52-week high price of INDEGENE (INDGN) is ₹615.50, while the 52-week low is ₹414.00. Currently trading at ₹592.10, the stock is 43.02% above its 52-week low and 3.8% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy INDEGENE stock at the current price?
Whether to buy INDEGENE stock at ₹592.10 depends on multiple factors. The stock is currently trading with a P/E ratio of 35.59 and P/B ratio of 4.55. Today's performance shows a loss of 0.65%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of INDEGENE and when is the next dividend?
INDEGENE offers a dividend yield of 0.37%, which means for every ₹100 invested at the current price of ₹592.10, you can expect to receive approximately ₹0.37 annually as dividends. The face value of the stock is ₹2.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of INDEGENE?
INDEGENE's key financial metrics include: P/E Ratio: 35.59, P/B Ratio: 4.55, ROE: 12.78%, ROCE: 14.54%, Dividend Yield: 0.37%, EPS: ₹16.62, Book Value: ₹130.29, and Debt-to-Equity: 0. The company's market cap stands at ₹14,288.59 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is INDEGENE stock performing today in the market?
INDEGENE stock opened at ₹596.00 and is currently trading at ₹592.10, showing a decline of ₹3.85 (0.65%). The intraday high is ₹600.35 and low is ₹588.00. The trading volume stands at 1,92,223 shares, indicating moderate market participation today.
08What is the P/E ratio of INDEGENE and what does it indicate?
INDEGENE has a Price-to-Earnings (P/E) ratio of 35.59, which means investors are willing to pay 35.59 for every ₹1 of earnings. With an EPS of ₹16.62, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about INDEGENE (INDGN) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.